Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Section for head and neck oncology

15 publications found

Aqrawi LA, Chen X, Hynne H, Amdal C, Reppe S, Aass HCD, Rykke M, Hove LH, Young A, Herlofson BB, Westgaard KL, Utheim TP, Galtung HK, Jensen JL (2020)
Cytokines Explored in Saliva and Tears from Radiated Cancer Patients Correlate with Clinical Manifestations, Influencing Important Immunoregulatory Cellular Pathways
Cells, 9 (9)
DOI 10.3390/cells9092050, PubMed 32911805

Astrup GL, Hofsø K, Bjordal K, Rustøen T (2020)
Cancer patients' diagnosis and symptoms and their family caregivers' self-efficacy and social support are associated with different caregiver reactions
Eur J Cancer Care (Engl), e13311
DOI 10.1111/ecc.13311, PubMed 32885524

Brandal P, Bergfeldt K, Aggerholm-Pedersen N, Bäckström G, Kerna I, Gubanski M, Björnlinger K, Evensen ME, Kuddu M, Pettersson E, Brydøy M, Hellebust TP, Dale E, Valdman A, Weber L, Høyer M (2020)
A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients
Acta Oncol
DOI 10.1080/0284186X.2020.1817977, PubMed 32902341

Clarke M, Mackay A, Ismer B, Pickles JC, Tatevossian RG, Newman S, Bale TA, Stoler I, Izquierdo E, Temelso S, Carvalho DM, Molinari V, Burford A, Howell L, Virasami A, Fairchild AR, Avery A, Chalker J, Kristiansen M, Haupfear K, Dalton JD, Orisme W, Wen J, Hubank M, Kurian KM et al. (2020)
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Cancer Discov, 10 (7), 942-963
DOI 10.1158/2159-8290.CD-19-1030, PubMed 32238360

Frič R, Due-Tønnessen BJ, Lundar T, Egge A, Kronen Krossnes B, Due-Tønnessen P, Stensvold E, Brandal P (2020)
Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood
Sci Rep, 10 (1), 9371
DOI 10.1038/s41598-020-66328-8, PubMed 32523021

Hauge T, Amdal CD, Falk RS, Johannessen HO, Johnson E (2020)
Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer - a cohort study
Acta Oncol, 59 (7), 859-865
DOI 10.1080/0284186X.2020.1750694, PubMed 32324079

Jeanmougin M, Håvik AB, Cekaite L, Brandal P, Sveen A, Meling TR, Ågesen TH, Scheie D, Heim S, Lothe RA, Lind GE (2020)
Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment
Mol Oncol, 14 (5), 1016-1027
DOI 10.1002/1878-0261.12668, PubMed 32171051

Kierulf-Vieira KS, Sandberg CJ, Waaler J, Lund K, Skaga E, Saberniak BM, Panagopoulos I, Brandal P, Krauss S, Langmoen IA, Vik-Mo EO (2020)
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061630, PubMed 32575464

König M, Osnes T, Bruland Ø, Sundby Hall K, Bratland Å, Meling TR (2020)
The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
Front Oncol, 10, 1402
DOI 10.3389/fonc.2020.01402, PubMed 32850452

Larsson C, Groote I, Vardal J, Kleppestø M, Odland A, Brandal P, Due-Tønnessen P, Holme SS, Hope TR, Meling TR, Fosse E, Emblem KE, Bjørnerud A (2020)
Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy
Magn Reson Imaging, 68, 106-112
DOI 10.1016/j.mri.2020.01.012, PubMed 32004711

Lundar T, Due-Tønnessen BJ, Frič R, Brandal P, Stensvold E, Due-Tønnessen P (2020)
Outcomes in adulthood after neurosurgical treatment of brain tumors in the first 3 years of life: long-term follow-up of a single consecutive institutional series of 97 patients
Childs Nerv Syst
DOI 10.1007/s00381-020-04859-1, PubMed 32814984

Rahman MA, Brekke J, Arnesen V, Hannisdal MH, Navarro AG, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, Haasz J, Oltedal L, Miletic H, Lundervold A, Lie SA, Goplen D, Chekenya M (2020)
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
Immun Inflamm Dis, 8 (3), 342-359
DOI 10.1002/iid3.315, PubMed 32578964

Stadskleiv K, Stensvold E, Stokka K, Bechensteen AG, Brandal P (2020)
Neuropsychological functioning in survivors of childhood medulloblastoma/CNS-PNET: The role of secondary medical complications
Clin Neuropsychol
DOI 10.1080/13854046.2020.1794045, PubMed 32729777

Stensvold E, Stadskleiv K, Myklebust TÅ, Wesenberg F, Helseth E, Bechensteen AG, Brandal P (2020)
Unmet rehabilitation needs in 86% of Norwegian paediatric embryonal brain tumour survivors
Acta Paediatr, 109 (9), 1875-1886
DOI 10.1111/apa.15188, PubMed 31977119

Witt Nyström P, Bratland Å, Minn H, Grau C (2020)
Ongoing and future clinical trials in particle therapy in the Nordic countries
Acta Oncol
DOI 10.1080/0284186X.2020.1792548, PubMed 32673134

 
Page visits: 442207